| |
Continuous (N=68)
|
Binary (N=255)
|
Ordinal (N=71)
|
Time-to-event (N=70)
|
Other (N=16)
|
|---|
|
Time frame
|
|
≤14 days
|
35 (51.5%)
|
79 (31.0%)
|
39 (54.9%)
|
11 (15.7%)
|
5 (31.3%)
|
|
15–30 days
|
26 (38.2%)
|
144 (56.5%)
|
30 (42.3%)
|
44 (62.9%)
|
8 (50.0%)
|
|
>30 days
|
7 (10.3%)
|
32 (12.5%)
|
2 (2.8%)
|
15 (21.4%)
|
3 (18.8%)
|
|
Evaluation of clinical course
|
|
Improvement
|
-
|
61 (23.9%)
|
-
|
53 (75.7%)
|
-
|
|
Worsening
|
-
|
135 (52.9%)
|
-
|
10 (14.3%)
|
-
|
|
Unknown
|
-
|
59 (23.1%)
|
-
|
7 (10.0%)
|
-
|
|
Sample size (trials with 1 arma)
|
| |
(N=24)
|
(N=57)
|
(N=9)
|
(N=16)
|
(N=3)
|
|
Mean (SD)
|
82.6 (99.8)
|
579.9 (634.8)
|
290.2 (219.3)
|
262.3 (303.4)
|
183.3 (104.1)
|
|
Median (IQR)
|
60 (47.5, 60)
|
300 (136, 1000)
|
250 (90, 466)
|
150 (121, 202.5)
|
150 (125, 225)
|
|
Sample size (trials with 2 armsa)
|
| |
(N=27)
|
(N=150)
|
(N=44)
|
(N=33)
|
(N=9)
|
|
Mean (SD)
|
730.5 (1675.1)
|
777.2 (1107.2)
|
336.8 (238.4)
|
464.6 (553.7)
|
1513.6 (2021.3)
|
|
Median (IQR)
|
250 (101, 284)
|
400 (131.3, 1144.5)
|
300 (109.5, 480)
|
278 (100, 554)
|
1444 (100, 1728)
|
|
Sample size (trials with ≥3 armsa)
|
| |
(N=17)
|
(N=48)
|
(N=18)
|
(N=21)
|
(N=4)
|
|
Mean (SD)
|
530.9 (990.9)
|
1225.2 (2347.2)
|
1481.1 (3228.3)
|
1034.2 (2223.6)
|
1042.5 (1431.5)
|
|
Median (IQR)
|
200 (200, 200)
|
320 (200, 1480)
|
120 (120, 283.5)
|
320 (200, 676)
|
475 (247.5, 1270)
|
- aA single drug with multiple doses that was placed under the same “Arm” in interventions was considered as one arm
- SD standard deviation, IQR interquartile range
